S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
Log in
OTCMKTS:HPST

Hempstract Stock Forecast, Price & News

$0.45
-0.04 (-8.16 %)
(As of 03/1/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.30
Now: $0.45
$0.47
50-Day Range
$0.38
MA: $0.56
$0.73
52-Week Range
$0.07
Now: $0.45
$2.17
Volume140,011 shs
Average Volume271,827 shs
Market Capitalization$44.86 million
P/E RatioN/A
Dividend YieldN/A
Beta-7.81
Hempstract, Inc. produces and sells cannabidiol (CBD) and cannabigerol solutions in the United States. It offers CBD isolate powder and distillate oil. The company was formerly known as Riverdale Oil and Gas Corporation and changed its name to Hempstract, Inc. in November 2020. Hempstract, Inc. is based in Warden, Washington.

Industry, Sector and Symbol

Industry Crude petroleum & natural gas
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:HPST
CUSIPN/A
CIKN/A
Phone800-748-5035
Employees2
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$44.86 million
Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

0.00 out of 5 stars

Medical Sector

1882nd out of 1,966 stocks

Crude Petroleum & Natural Gas Industry

237th out of 247 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$0.45
-0.04 (-8.16 %)
(As of 03/1/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HPST News and Ratings via Email

Sign-up to receive the latest news and ratings for HPST and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Hempstract (OTCMKTS:HPST) Frequently Asked Questions

What stocks does MarketBeat like better than Hempstract?

Wall Street analysts have given Hempstract a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Hempstract wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Hempstract?

Hempstract saw a increase in short interest in February. As of February 12th, there was short interest totaling 34,800 shares, an increase of 3,063.6% from the January 28th total of 1,100 shares. Based on an average daily trading volume, of 425,400 shares, the days-to-cover ratio is presently 0.1 days.
View Hempstract's Short Interest
.

Who are Hempstract's key executives?

Hempstract's management team includes the following people:
  • Mr. Ronald M. Herzfeld, CEO & Director
  • Mr. Michael B. Glazer, Sec.
  • Ms. Linda Ellis, VP

Who are some of Hempstract's key competitors?

What is Hempstract's stock symbol?

Hempstract trades on the OTCMKTS under the ticker symbol "HPST."

How do I buy shares of Hempstract?

Shares of HPST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Hempstract's stock price today?

One share of HPST stock can currently be purchased for approximately $0.45.

How much money does Hempstract make?

Hempstract has a market capitalization of $44.86 million.

How many employees does Hempstract have?

Hempstract employs 2 workers across the globe.

What is Hempstract's official website?

The official website for Hempstract is www.hempstractlabs.com.

Where are Hempstract's headquarters?

Hempstract is headquartered at 16152 Beach Boulevard, Huntington Beach CA, .

How can I contact Hempstract?

Hempstract's mailing address is 16152 Beach Boulevard, Huntington Beach CA, . The company can be reached via phone at 800-748-5035.


This page was last updated on 3/2/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.